Zacks Investment Research on MSN
FDA grants priority review to BridgeBio's dwarfism drug filing
BridgeBio Pharma BBIO announced that the FDA accepted its regulatory filing seeking approval for the investigational oral ...
The Food and Drug Administration says its ongoing safety review of the nation’s main abortion pill will continue into next ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Clene (NASDAQ:CLNN) said it plans to submit a new drug application to the U.S. Food and Drug Administration at the beginning ...
The US Food and Drug Administration (FDA) recently released a transparency roadmap outlining its achievements in FY 2026 and ...
Tuesday, BridgeBio Pharma, Inc. ( BBIO) announced that the U.S. Food and Drug Administration has accepted for filing its New Drug Application with Priority Review for oral infigratinib for the ...
TAIPEI, Taiwan, Aug. 27, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (“SL Science” or the “Company”) (NASDAQ: SLBT), a Taiwan-headquartered biomedical company specializing in innovative ...
A Calculated Delay The Trump Justice Department has mapped out its coming attack on mifepristone — much thirsted for ...
When a new drug application (NDA) or biologics license application (BLA) is deemed incomplete by the US Food and Drug Administration (FDA), the agency can decide not to review the application. So when ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results